• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers deliver cardiac stem cell therapy in preclinical trial using refillable patch

June 11, 2018 By Sarah Faulkner

Researchers have developed a small device designed to halt the effects of a heart attack by delivering a stem cell therapy directly to damaged cardiac tissue.

In a study published in Nature Biomedical Engineering, researchers from Harvard University, the Massachusetts Institute of Technology, the National University of Ireland Galway and Trinity College Dublin reported that the device improved heart function in rats that received multiple doses of the stem cell therapy over the course of four weeks.

The device, dubbed ‘Therepi’, features a refillable reservoir that is made out of a gelatin-based polymer. The reservoir is shaped like a sphere that’s been sliced in half – the flat half includes a semi-permeable membrane that allows drugs to be delivered directly to damaged tissue.

When used to deliver a stem cell therapy, the device’s reservoir keeps the stem cells in place while the cells churn out healing compounds that are passed through the device’s membrane to the heart tissue.

The device is also refillable, according to the researchers. A refill line connects directly to the reservoir via a port through the user’s skin.

Testing the product on rats, researchers gave multiple doses of stem cells and assessed the therapy’s efficacy using echocardiography and a pressure-volume catheter. They observed that the rats that received multiple doses of stem cells experienced greater improvement in heart function compared to the rats that received a single dose or no dose.

“After a heart attack we could use this device to deliver therapy to prevent a patient from getting heart failure,” co-first author Ellen Roche said in prepared remarks. “If the patient already has some degree of heart failure, we can use the device to attenuate the progression.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: Harvard University, Massachusetts Institute of Technology

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS